A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
| Autor: | Jing Wang, Sheryl Coppola, Kristian M. Bowles, Al-Ola Abdallah, Emma Arriola, Orlando F. Bueno, Maria-Victoria Mateos, Gudrun Mander, Lura Morris, Jeremy A. Ross, Cristina Gasparetto |
|---|---|
| Přispěvatelé: | AbbVie Pharmaceuticals |
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty BCL2 Immunomodulatory agent Phases of clinical research Neutropenia Dexamethasone Targeted therapy Venetoclax chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Adverse effect Multiple myeloma Aged Lenalidomide Sulfonamides business.industry Hematology Bridged Bicyclo Compounds Heterocyclic Pomalidomide medicine.disease Plasma cell dyscrasia Progression-Free Survival Thalidomide Tolerability chemistry Female Multiple Myeloma business medicine.drug |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| Popis: | © 2021 The Authors. [Background]: Venetoclax is a selective BCL-2 inhibitor with clinical activity in relapsed/refractory multiple myeloma (RRMM). Combinations of venetoclax with agents that have complementary mechanisms of action may improve venetoclax efficacy in RRMM. This study evaluated venetoclax with pomalidomide and dexamethasone (VenPd) in RRMM. [Patients and Methods]: This phase II open label study (NCT03567616) evaluated VenPd in patients with RRMM who had received ≥ 1 prior therapy and were refractory to lenalidomide. Venetoclax was administered orally daily for days 1 to 28, pomalidomide was administered orally daily for days 1 to 21, and dexamethasone was administered weekly for each 28-day cycle. The primary objective was to characterize the safety and tolerability of VenPd. The secondary objectives were to evaluate the efficacy and pharmacokinetics. The study was terminated early due to partial clinical hold and decision to pursue biomarker driven strategy. [Results]: Eight patients were enrolled. Patients had a median age of 67.5 years. All patients received 400 mg venetoclax; 4 patients experienced dose-limiting toxicities and the dose was not escalated. All patients had a grade ≥ 3 adverse event, and the most common was neutropenia (n = 6); cytopenias were the most prevalent adverse events. Five patients (63%) had a confirmed response, and the median duration of response was 12.9 months. The median progression-free survival was 10.5 months. [Conclusions]: Given the limited enrollment, no clear safety or efficacy conclusions about VenPd can be drawn. Preliminary safety data, particularly the occurrence of cytopenias, can be used to guide dosing strategies for future combinations of venetoclax with immunomodulatory agents. AbbVie Inc is a private corporation, and funding is not associated with a grant number. Funding information is correct as stated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|